Prostate Carcinoma Clinical Trial
— GIFTSOfficial title:
Genetic Information to Inform Treatment and Screening (GIFTS) Study for Prostate Cancer
Verified date | February 2024 |
Source | Fred Hutchinson Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This trial studies the role of inherited (present at birth) mutations in cancer risk genes such as BRCA2, BRCA1, ATM, CHEK2, and others in relation to prostate cancer. This study may help researchers understand the frequency and importance of inherited mutations in cancer risk genes in patients with prostate cancer and potentially help identify better ways to treat cancer in patients who have a mutation in one of these genes.
Status | Enrolling by invitation |
Enrollment | 1360 |
Est. completion date | August 31, 2028 |
Est. primary completion date | August 31, 2028 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 35 Years to 89 Years |
Eligibility | Inclusion Criteria: Case Ascertainment - Signed informed consent form providing agreement for germline genetic testing, use and release of health and research information - Male aged 35 to 89 years - Diagnosis of prostate cancer - Resident of Washington state - Willing to complete a questionnaire (online or on paper) to provide basic demographic information, family cancer history, and health history - Willing and able to provide a saliva sample - United States (U.S.) mailing address Inclusion Criteria: Family Recruitment - Signed informed consent form providing agreement for germline genetic testing, use and release of health and research information - Males aged 35 to 89 years - Willingness to complete a questionnaire (online or on paper) to provide basic demographic information, family cancer history, and health history - Willingness and ability to provide a saliva sample - U.S. mailing address Exclusion Criteria: Case Ascertainment - Unable to provide informed consent, e.g. decisional impairment - Prior bone marrow transplant - Currently under treatment for a hematologic malignancy - Study team members Exclusion Criteria: Family Recruitment - Unable to provide informed consent, e.g. decisional impairment - Prior bone marrow transplant - Currently under treatment for a hematologic malignancy - Study team members |
Country | Name | City | State |
---|---|---|---|
United States | Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Fred Hutchinson Cancer Center | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Identification of a population-based cohort of men with prostate cancer (PC) and germline deoxyribonucleic acid (DNA) repair gene (gDRG) mutations | Identification to be determined through the Washington State Cancer Registry and by genetic testing on saliva samples for inherited mutations in cancer risk genes such as BRCA2, BRCA1, ATM, and others in prostate cancer. | From the start of study through death (up to 20 years) | |
Primary | Clinical, pathologic, and molecular predictors of gDRG mutation carriers for men with PC | Predictors to be identified by analyzing information provided by participants on their health history and potentially further testing or chart review on participants who consent to future contact. | From the start of study through death (up to 20 years) | |
Primary | Utility and feasibility of cascade genetic testing through use of family history of men with PC identified to have gDRG mutations | To be determined by collection of information about participants' family history and subsequent analysis of cascade genetic testing outcomes. | From the start of study through death (up to 20 years) | |
Primary | Identification of a cohort of men with gDRG mutations without PC | Identification to be determined through family history of men with PC identified through the Washington State Cancer Registry and by genetic testing on saliva samples for inherited mutations in cancer risk genes such as BRCA2, BRCA1, ATM, and others in prostate cancer. | From the start of study through death (up to 20 years) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04457232 -
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation
|
Phase 1 | |
Active, not recruiting |
NCT03661437 -
Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy
|
Early Phase 1 | |
Completed |
NCT02337465 -
KV-CBCT and Ultrasound Imaging in Guiding Radiation Therapy in Patients With Prostate, Liver, or Pancreatic Cancer
|
N/A | |
Completed |
NCT03013413 -
Ultrasound-Based Imaging Using the Aixplorer System in Diagnosing Prostate Cancer in Patients Undergoing Biopsy
|
N/A | |
Recruiting |
NCT06037863 -
Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial
|
N/A | |
Active, not recruiting |
NCT03580499 -
Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy
|
N/A | |
Completed |
NCT03326440 -
Virtual Environment Radiotherapy to Improve Patients' Compliance to Radiotherapy (RT) in Prostate Cancer
|
N/A | |
Recruiting |
NCT04597359 -
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
|
Phase 2 | |
Active, not recruiting |
NCT03263650 -
Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC
|
Phase 2 | |
Active, not recruiting |
NCT04600336 -
Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04299620 -
Micro-Ultrasound for the Detection and Localization of Prostate Cancer Tumors in Patients Undergoing Radical Prostatectomy
|
N/A | |
Completed |
NCT04976257 -
Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion
|
Early Phase 1 | |
Completed |
NCT02957981 -
The Genetic Education for Men Trial: Web-Based Education vs. Standard Care
|
N/A | |
Withdrawn |
NCT03408561 -
Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer
|
N/A | |
Enrolling by invitation |
NCT06347809 -
DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine
|
||
Recruiting |
NCT05519878 -
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
|
N/A | |
Recruiting |
NCT02994758 -
Development of Diagnostics and Treatment of Urological Cancers
|
N/A | |
Completed |
NCT01497431 -
Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT00002540 -
Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)
|
N/A | |
Completed |
NCT03101046 -
Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic
|
Phase 2 |